Stimulants for the control of hedonic appetite

The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behaviour. Stimulant medications...

Full description

Saved in:
Bibliographic Details
Main Authors: Alison Sally Poulton (Author), Emily Jane Hibbert (Author), Bernard Linton Champion (Author), Ralph Kay Heinrich Nanan (Author)
Format: Book
Published: Frontiers Media S.A., 2016-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_db01d65a57d446d488eecc7a29e5208d
042 |a dc 
100 1 0 |a Alison Sally Poulton  |e author 
700 1 0 |a Emily Jane Hibbert  |e author 
700 1 0 |a Bernard Linton Champion  |e author 
700 1 0 |a Ralph Kay Heinrich Nanan  |e author 
245 0 0 |a Stimulants for the control of hedonic appetite 
260 |b Frontiers Media S.A.,   |c 2016-04-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2016.00105 
520 |a The focus of this paper is treatment of obesity in relation to the management of hedonic appetite. Obesity is a complex condition which may be potentiated by excessive reward seeking in combination with executive functioning deficits that impair cognitive control of behaviour. Stimulant medications address both reward deficiency and enhance motivation, as well as suppressing appetite. They have long been recognised to be effective for treating obesity. However, stimulants can be abused for their euphoric effect. They induce euphoria via the same neural pathway that underlies their therapeutic effect in obesity. For this reason they have generally not been endorsed for use in obesity. Among the stimulants, only phentermine (either alone or in combination with topiramate) and bupropion (which has stimulant-like properties and is used in combination with naltrexone), are approved by the United States Food and Drug Administration (FDA) for obesity, although dexamphetamine and methylpenidate are approved and widely used for treating attention deficit hyperactivity disorder (ADHD) in adults and children. Experience gained over many years in the treatment of ADHD demonstrates that with careful dose titration, stimulants can be used safely. In obesity, improvement in mood and executive functioning could assist with the lifestyle changes necessary for weight control, acting synergistically with appetite suppression. The obesity crisis has reached the stage that strong consideration should be given to adequate utilisation of this effective and inexpensive class of drug. 
546 |a EN 
690 |a Obesity 
690 |a Phentermine 
690 |a appetite suppressants 
690 |a Dexamphetamine 
690 |a Reward deficiency 
690 |a hedonic appetite 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 7 (2016) 
787 0 |n http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00105/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/db01d65a57d446d488eecc7a29e5208d  |z Connect to this object online.